Sierra School of Gilbert Expands Services With Opening of Adult Day Program

Focus on Purposeful Activities and Enhancing Daily Living Skills for Young Adults 18-26 Who Are Exiting School Services

GILBERT, Ariz., Nov. 12, 2020 (GLOBE NEWSWIRE) — Specialized Education Services, Inc. (SESI), a premier provider of education services for K-12 students who require additional educational and positive behavioral supports, announced the opening of its Adult Day Program (DTA) at the Sierra School of Gilbert. The program, which serves young adults (ages 18-26) with developmental disabilities, centers on recreational activities with an emphasis on community integration. Approved by the Arizona Division of Developmental Disabilities (DDD/DES), the DTA program provides a resource for those who are exiting school services.

When an individual enrolls, their programmatic goals are personally designed. Staff provide coaching that expands members’ repertoire of essential skills in areas like community knowledge, social awareness, personal organization, basic communication and leisure activities. Each member is encouraged to participate to their full potential in a supportive space that embraces community, friendship, and neurodiversity.

“We are excited to offer the program as an opportunity for young adults who are not headed to traditional post-secondary options but want to stay active and continue learning in a supportive space,” said Jessica Mayfield, Director of Clinical and Specialty Services, Sierra School of Gilbert. “Our expert staff can support these individuals with mastering life skills in an environment that also encourages socialization and having fun.”

The DTA program runs Monday-Friday from 8 a.m. to 3 p.m. and is currently accepting new members, with priority given to former Sierra School students. Members from the broader community are also invited to learn more about the program. Transportation to the program is available for members living within a 10-mile radius of the campus (875 South Cooper Road, Gilbert). For more information on services and enrollment, visit: https://sesischools.com/locations/arizona/sierra-school-of-gilbert/.

About Specialized Education Services, Inc. 

Specialized Education Services, Inc. (SESI), a division of FullBloom, is a premier provider of education services for K-12 students who require additional educational and positive behavioral supports to overcome challenges that impede success in a traditional school setting. SESI partners with school districts to offer professional development and to run in-district classrooms and stand-alone schools that meet the academic, behavioral, social, and emotional needs of special and alternative education students with Autism Spectrum Disorders, Learning, Emotional and other disabilities. Implementing a signature, research-based education model that incorporates supportive therapies, life skills training, and workforce development programs, as well as professional learning for special education teachers, SESI guides students toward success in and out of the classroom. It proudly serves over 3,000 students through over 50 day schools and 80+ in-district classrooms and partners with over 500 school districts. SESI is accredited by Cognia (formerly AdvancED). www.sesischools.com.

Press Contact 
Jennifer Leckstrom
RoseComm for SESI 
(215) 681-0770
[email protected]

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon- PGEN, XON; IMPORTANT DEADLINE –Precigen, Inc. f/k/a Intrexon Corporation– PGEN, XON

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017  through September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Precigen, Inc. f/k/a Intrexon Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:  (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Company’s financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 4, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Akers Biosciences, Inc.

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Rowley Law PLLC is investigating potential securities law violations by Akers Biosciences, Inc. (NASDAQ: AKER) and its board of directors concerning the proposed merger of the company with MyMD Pharmaceuticals, Inc. Akers Biosciences stockholders will own 20% of the combined company. The transaction is expected to close in the first half of 2021.

If you are a stockholder of Akers Biosciences, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/aker/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).  

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com

Attorney Advertising. Prior results do not guarantee a similar outcome.

Cision View original content:http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-akers-biosciences-inc-301172322.html

SOURCE Rowley Law PLLC

Vuzix Continues to Receive Multiple Follow-On M400 Smart Glasses Orders from Both Resellers and End Customers to Support Business Operations Amid COVID-19 Pandemic

– A Fortune 500 engine manufacturer and a pharmaceutical air transportation solution provider place follow-on orders

– Brochesia places a follow-on order to support industrial production, construction, transportation and marine customers

PR Newswire

ROCHESTER, N.Y., Nov. 12, 2020 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Company has received initial follow-on orders and delivered M400 Smart Glasses kits to support remote support and training after rapid and successful proof of concept evaluations were performed by two new customers. The COVID-19 global pandemic continues to be an accelerant for the adoption within the enterprise smart glasses.

The first customer is a Fortune 500 engine manufacturer and distributor and after a rapid and successful proof of concept evaluation was completed this summer using a hand full of M400 Smart Glasses to support technicians with remote guidance and training, the customer placed a follow-on order that was recently delivered for broader deployment of M400 Smart Glasses. 

The second company is leading global provider of pharmaceutical air transportation solutions and after a rapid and successful proof of concept evaluation using one M400 Smart Glasses to support technicians with remote guidance and training, the company placed a follow-on order for many more M400 Smart Glasses that was recently delivered. 

“Over the last few quarters, we have witnessed many customers both large and small within the enterprise smart glasses industry moving faster between pilot evaluation and volume deployments into their operations.  These two customers are proof points and prime examples of how Vuzix Smart Glasses are being effective out of the box to deliver remote guidance and training to provide sizable benefits for our customers,” said Paul Travers, Vuzix President and Chief Executive Officer. “We look forward to supporting these customers as they continue to deploy Vuzix Smart Glasses across their operations.”

In addition to these two direct customers, Vuzix also received a follow-on M400 Smart Glasses order (unit total not disclosed due to competitive reasons) from Brochesia, a software solution provider based in Italy that  sells smart glasses based solution into enterprise to support manufacturing, healthcare, field service and logistics.

After successfully piloting the Vuzix M400 Smart glasses, Brochesia will be delivering devices to enterprise end customers to be deployed in support of industrial production, construction, transportation and the marine industry. 

“The Vuzix M400 Smart Glasses powered by the Brochesia software suite have been well received by our customers and we are pleased to see them moving from forward from pilots to production,” commented Claudia Simon, Chief Operating Officer of Brochesia.

“The Brochesia software platform with the Vuzix M400 Smart Glasses are being put to work across multiple enterprise verticals,” said Paul Travers, Vuzix President and Chief Executive Officer. “Vuzix looks forward to supporting Brochesia’s as they continue to roll out their Vuzix Smart Glasses-based solution across their extensive customer base.”

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company’s products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 179 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2020 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan. For more information, visit Vuzix websiteTwitter and Facebook pages.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to the Vuzix Smart Glasses, our business opportunities with the above mentioned firms, along the ultimate success and future business opportunities with these firms, and among other things the Company’s leadership in the Smart Glasses and AR display industry. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Media and Investor Relations Contact:

Ed McGregor, Director of Investor Relations, Vuzix Corporation [email protected] Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, Suite A, West Henrietta, NY 14586 USA,
Investor Information – [email protected]www.vuzix.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vuzix-continues-to-receive-multiple-follow-on-m400-smart-glasses-orders-from-both-resellers-and-end-customers-to-support-business-operations-amid-covid-19-pandemic-301172313.html

SOURCE Vuzix Corporation

HighPoint Partners with UiPath to Improve Citizen Experiences through Automation

Partnership enables government agencies to achieve operational effectiveness and improve customer experiences through RPA

HERNDON, Va., Nov. 12, 2020 (GLOBE NEWSWIRE) — HighPoint, a provider of IT and digital services for government agencies, announced today that it is partnering with robotic process automation (RPA) software provider, UiPath, to automate high-volume, repetitive processes that will improve government efficiency and customer experiences.

Through this partnership, HighPoint will help government agencies implement RPA to build more efficient, streamlined, and responsive organizations, while driving innovation and achieving digital transformation objectives. HighPoint will bring its experience with large-scale government contact centers and high-volume repositories to identify areas of improvement, reduce redundancies, and improve productivity and customer experience. HighPoint understands the evolution of today’s contact centers and will help agencies digitally evolve by leveraging emerging technologies, tools, and processes.

UiPath has a vision to deliver A Robot for Every Person, one where companies enable every employee to use, create, and benefit from the transformative power of automation to liberate the boundless potential of people. Only UiPath offers an end-to-end platform for automation, combining the leading RPA solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed.

HighPoint also launched an Intelligent Automation Center of Excellence (CoE), which will be led by John Cyrus, Director of Emerging Technologies and IT Strategy. Prior to joining HighPoint, John Cyrus was the co-lead of the RPA CoE at the U.S. Patent and Trademark Office.

“HighPoint is committed to making information more available for government agencies and the people they serve,” said Cyrus. “We are excited to partner with UiPath to bring our clients innovation that will increase efficiency, accelerate digital transformation goals, and improve citizen and employee experiences.”

About HighPoint

HighPoint helps government agencies elevate customer and employee experiences. From contact centers and training to digital and data services, our team works with government agencies to more efficiently integrate the people, processes and technology that help government deliver on the needs of citizens and employees. HighPoint delivers services for 13 government clients including the Centers for Medicare and Medicaid Services, Office of the Comptroller of Currency, Department of State, Defense Logistics Agency and Department of Housing and Urban Development.

HighPoint is a privately held company founded in 2006 with employees across offices in Indianapolis, Indiana; Baltimore, Maryland; and Herndon, Virginia. To learn more, visit highpointglobal.com.

Contact:
Kim Miller
Director, Marketing and Communications
[email protected]

 

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

— Ten Additional Technology Leaders Join Founding Members to Together Advance Industry Roadmap, Set Stage for Widespread Adoption of New Long-term Storage Option —

— Announcement at Flash Memory Summit —

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA data storage. These founding companies, alongside member organizations, will work together to create a comprehensive industry roadmap that will help the industry achieve interoperability between solutions and help establish the foundations for a cost-effective commercial archival storage ecosystem for the explosive growth of digital data.

“DNA is an incredible molecule that, by its very nature, provides ultra-high-density storage for thousands of years,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By joining with other technology leaders to develop a common framework for commercial implementation, we drive a shared vision to build this new market solution for digital storage.”

DNA data storage has the potential to deliver a true low-cost archival data storage solution. While current storage technologies have limited longevity and require data migration for long-term data storage, DNA provides a stable format storage medium that is durable for thousands of years when properly stored. In addition, DNA enables cost effective and rapid duplication. Importantly, it is incredibly dense, with 10 full length digital movies fitting into a volume the size of a single grain of salt. Digital data stored in DNA can be stored in a variety of containers including capsules, pellets or encased in glass beads.

“At Microsoft Research, we proactively address the future challenges of technology, with sustainability in mind,” commented Karin Strauss, Ph.D., senior principal research manager at Microsoft. “In collaboration with University of Washington, we have demonstrated a fully automated end-to-end system capable of storing and retrieving data from DNA, and we have separately stored 1GB of data in DNA synthesized by Twist and recovered data from it. We’re encouraged by the potential for more sustainable data storage with DNA and look forward to collaborating with others in the industry to explore early commercialization of this technology.”

By 2024, 30% of digital businesses will mandate DNA storage trials, addressing the exponential growth of data poised to overwhelm existing storage technology.1

“There is an unmet need for a new long-term archival storage medium that keeps up with the rate of digital data growth,” said Steffen Hellmold, vice president corporate strategic initiatives, Western Digital. “We estimate that almost half of the data storage solutions shipped in 2030 will be used to archive data as the overall temperature of data is cooling down. We are committed to providing a full portfolio of storage solutions addressing the demand for hot, warm and cold storage.”

“A key component of a DNA data storage system is its ability to read back the digital information when needed,” stated Alex Aravanis, M.D., Ph.D., chief technology officer at Illumina. “We believe Illumina’s innovative sequencing technology will be critical in enabling this market at commercial scale and look forward to collaborating with other leaders in their respective fields to make this a viable, long-term solution for archival storage.”

Twist Bioscience, Illumina, Western Digital and Microsoft are joining the Alliance as founding members. In addition to developing an industry roadmap, the DNA Data Storage Alliance plans to develop use cases in various markets and industries as well as promote and educate the larger storage community to promote adoption of this future solution. The following organizations have joined the alliance as members:

The Alliance welcomes additional participation from organizations within DNA and data storage industries that would like to contribute to this emerging ecosystem.

How to Store Digital Data in DNA

To store data in DNA, first, a data file is converted from its digital sequence of 0’s and 1’s into a DNA sequence of A’s, C’s, T’s and G’s. The DNA data file is then synthesized (“written”) in short segments of DNA (200 to 300 bases long) and stored. In addition to storing part of the data file, each short segment contains an index to indicate its place within the overall data file. To retrieve the data, the segments are sequenced (“read”) and then decoded back into the original file. One feature of the indexing system is it allows part of the file to be biologically recovered (“random access”) before sequencing, so only data of interest is sequenced. In addition, all data is recovered error-free because error-correcting algorithms are used during the encode/decode process. For a short video of the process watch: https://www.youtube.com/watch?v=LTnJWxCO3M4.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

About Western Digital

Western Digital creates environments for data to thrive. As a leader in data infrastructure, the company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Our data-centric solutions are comprised of the Western Digital®, G-Technology™, SanDisk®, and WD® brands.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation, the ability of the Alliance to advance DNA data storage, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; scientific unknowns and new information relating to the SARS-CoV-2 virus; the duration, extent and impact of the COVID-19 pandemic; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Western Digital Forward-Looking Statements Disclaimer

This news release contains certain forward-looking statements, including expectations regarding the future applications, advances and success of DNA data storage and Western Digital’s expectations regarding its portfolio of storage solutions. There are a number of risks and uncertainties that may cause these forward-looking statements to be inaccurate including, among others: future responses to and effects of the COVID-19 pandemic; volatility in global economic conditions; impact of business and market conditions; impact of competitive products and pricing; our development and introduction of products based on new technologies and expansion into new data storage markets; risks associated with cost saving initiatives, restructurings, acquisitions, divestitures, mergers, joint ventures and our strategic relationships; difficulties or delays in manufacturing or other supply chain disruptions; hiring and retention of key employees; our high level of debt and other financial obligations; changes to our relationships with key customers; disruptions in operations from cyberattacks or other system security risks; actions by competitors; risks associated with compliance with changing legal and regulatory requirements and the outcome of legal proceedings; and other risks and uncertainties listed in Western Digital’s filings with the Securities and Exchange Commission (the “SEC”), including Western Digital’s Form 10-K filed with the SEC on August 28, 2020, to which your attention is directed. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Western Digital undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

1Gartner Press Release, “Gartner Unveils Top Predictions for IT Organizations and Users in 2021 and Beyond”, October 21, 2020 https://www.gartner.com/en/newsroom/press-releases/2020-10-21-gartner-unveils-top-predictions-for-it-organizations-and-users-in-2021-and-beyond

Contacts for Twist Bioscience:

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Media Contact:

Angela Bitting

925- 202-6211

[email protected]

Contacts for Western Digital

Media Contact:

Lisa Neitzel

1-408-717-7607

[email protected]

Investor Contact:

T. Peter Andrew

+1-949-672-9655

[email protected]

[email protected]

Contact for Illumina:

Dr. Karen Birmingham

1-646-355-2111

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Research Technology Security Genetics Software Biotechnology Pharmaceutical Health Data Management Science

MEDIA:

Logo
Logo

PyroGenesis Provides Update on its Iron Ore Pelletization Torch Business

MONTREAL, Nov. 12, 2020 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (TSX-V: PYR; OTCQB: PYRNF; FRA: 8PY) (the “Company” or “PyroGenesis”), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and products, is pleased to provide an update on the Company’s iron ore pelletization plasma torch business.

Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, provides this update in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors, and analysts:


Q


1


.


For those


who


are new to the story, could you please


provide


us


with


some background on your


high-powered


(~ 1 MW range)


plasma torch


business


and how


it


relate


s


to


the


iron ore


pelletization


industry


?


A.
Most certainly.

For background, pelletization is the process in which iron ore is concentrated before shipment, thus significantly reducing the cost of transportation, and providing a required feedstock for blast furnaces. In conventional technologies, the process heat is provided by fuel oil or natural gas burners (both environmentally damaging). The combustion, in the burners, of fossil fuels results in the production of greenhouse gases (“GHG”), mainly CO2. Plasma torches, by contrast, utilize renewable electricity and as such offer an environmentally attractive alternative to fossil fuel burners.

In January 2019, PyroGenesis was contracted for a 900kW plasma torch with a client which we later disclosed to be RISE Energy Technology Center AB (“RISE”) of Sweden. RISE was engaged in addressing the Swedish government’s commitment to zero carbon emissions1; namely that within the iron ore pelletization industry. The ultimate objective was to determine the benefits, if any, of replacing traditional fossil fuel burners used in iron ore pelletization with plasma torches. We delivered the plasma torch and completed testing in 9 months.

Of note, PyroGenesis has a patented process to replace fossil fuel burners with PyroGenesis’ clean burning plasma torches, thereby reducing GHG emissions, for the iron ore pelletization industry.


Q2.


S


o,


P


yroGenesis


has the patent to replace f


ossil


f


uel


burners


with plasma torches in


the


iron ore


pelletization


industry


?


A.
Yes, we do. In other industries, we expect to leverage off of our first mover advantage developed in the iron ore pelletization industry.


Q


3


.


T


he RISE contract went well.


What happened next


?


A.
Our original goal was simply to have our torches be a contender in Sweden’s strategy to reduce GHG emissions in the iron ore pelletization industry. What we did not realize at the time, was the impact this would have on the industry as a whole. As noted above, we successfully completed the RISE contract in 9 months, which once made public, had a resounding effect as we apparently were addressing a significant concern in the industry with respect to GHG emissions reduction. Given this interest, we were approached by several companies in the industry which we have come to term Client A, B and C. Two of the three wanted to immediately engage in a modelling contract, and the third is in the process of considering such. We prefer to engage in a modelling-first-step as it helps quantify parameters that may be specific to the client.

Modelling is a computer-based simulation of the performance of PyroGenesis’ proprietary plasma torches using the specific parameters in a particular iron ore pelletization plant. The goal is to demonstrate the benefits of replacing existing fossil fuel burners with plasma torches and/or identify unanticipated or hidden costs/side effects.

To date, between RISE and the modelling we have done, two of the most important benefits demonstrated were i) that replacing fossil fuel burners with plasma torches was a simple replacement, plug and play process, and ii) that PyroGenesis’ proprietary plasma torches significantly reduce GHG emissions. There have been no unanticipated or hidden costs.

Furthermore, we have noticed that our patented plasma torch technology, not only has economic and environmental advantages, but may also address environmental policies and legislation being implemented worldwide. For example, the European Union (EU), as part of the EU’s 2030 climate and energy framework and contribution to the Paris Agreement2, has put in place legislation to reduce emissions by at least 40% by 2030.

As a result, many companies in the field are implementing business strategies directed at reducing GHG emissions. As an example, a major international iron ore pelletizer has dedicated approx. US $2B towards their goal of reducing their carbon emission by 33% by 20303.

We believe PyroGenesis is uniquely positioned to address such opportunities.


Q


4


.


Interesting…so


replacing fossil fuel


burners


with plasma torches might be able to


eco


nomically


,


and


significantly


,


reduce the


GHG


emissions


in the iron ore


pelletization


industry


?


A

. Correct.

Management has internally estimated that a typical pellet plant producing 10 million metric tonnes of pellets annually emits approximately one million metric tonnes of CO24. The total world pellet production of 400 million metric tonnes of pellets represents a potential market for torch sales in excess of $10B worldwide. The world pellet industry generates about 40 million metric tonnes of CO2 every year. The use of plasma torches running off a clean electrical grid would reduce these emissions significantly. For reference, 40 million tonnes of CO2 represent the combined yearly emissions of 8.7 million US passenger vehicles5.

The impact of replacing fossil fuel burners with plasma torches not only resonates in the iron ore pelletization industry, where we are patent protected, but also in other industries such as the aluminum, cement and glass industries, who are also pressured to reduce GHG emissions.


Q


5


.


What is your


business model


for replacing fossil fuel burners


with plasma torches


, specifically


in the iron ore


pelletization


industry which seems to be the low





hanging fruit


?


A.
This is a very good question.

Our offering is geared to address the need to develop fossil fuel free energy-mining-iron-steel value chain and thereby provide a basis for governance and industrial strategies for transformative change. Until recently, the business model was simply to sell torches (with an internal target of $3MM NPV per torch) with the recurring revenue derived from typical maintenance and spare parts contracts.

We now have come to appreciate the economics of leasing torches instead of an outright sell. This model has clear advantages to both parties; little-to-no CAPEX to the buyer, healthy recurring revenue stream to the seller. At this stage, we see this to be the fastest way to grow this business segment, and is a significant strategy-shift for the Company as it relates to this offering, and which we expect will play a key role in our position/ongoing discussions with clients.


Q


6.


Woul


d


n’t this leasing model be capital intensive?


A.
Yes and no.

It is capital intensive of course, however, there are major leasing companies we can team up with to provide this service. Given the size and credit worthiness of the client, together with a proven technology, we do not see this to be an issue. Had the client been small, their credit worthiness not be conducive to leasing, or the technology not be proven, then the burden would be on PyroGenesis to provide that capital, and we do not see ourselves engaging in that type of financing.


Q


7


.


In


closing, can you


give us


a status


/upda


t


e o


n


the existing


agreements


/contracts


u


nder discussion


?


A.
Certainly.

All of our projects are on track and progressing nicely. As previously disclosed on September 1st, 2020, we have received a draft contract from Client A, which is still in the final stages of completion. The fact that we received this contract from Client A, on the heels of a successful modelling contract, who is a significant player in the industry, clearly demonstrates the impact that PyroGenesis’ proprietary plasma torches are having on iron ore pelletization GHG reduction strategies. If signed, and successfully deployed, one might expect they would start a program to replace their fossil fuel burners with PyroGenesis’ plasma torches. Although nothing is certain, we are definitely on the right track with Client A.

Client B has finalized their modelling contract, and like Client A, has moved to contract negotiations and requested a quote for an initial order of four torches which we have recently provided.

Client C is moving forward as well. We are confident that they will agree to enter into a modeling contract before an initial order of torches is placed. We find this to be the most prudent next step.

We are also in discussion with potential clients in other industries to replace their fossil fuel burners with PyroGenesis’ plasma torches.

About
PyroGenesis
Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to
a number of
risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the closing and timing of the Company’s public offering. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, including under “Risk Factors” in the Company’s most recent annual information form, which filings can be found under the Company’s profile at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward- looking statements either
as a result of
new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the
Toronto Stock Exchange
nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President, Investor Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINK: http://www.pyrogenesis.com/

1 https://www.ssab.com/company/sustainability/sustainable-operations/hybrit
2 https://ec.europa.eu/clima/policies/strategies/progress_en
3 http://www.vale.com/brasil/EN/sustainability/Pages/carbonneutral.aspx
4 M. Huerta, J. Bolen, M. Okrutny, I. Cameron and K. O’Leary, “Guidelines for Selecting Pellet Plant Technology”, Iron Ore Conference 2015 Proceedings, Perth, WA, July 13-15, 2015
5 https://www.epa.gov/greenvehicles/greenhouse-gas-emissions-typical-passenger-vehicle 

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Tactile Systems Technology, Inc.– TCMD; IMPORTANT NOV. 30 DEADLINE –TCMD

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD) from May 7, 2018 through June 8, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tactile Systems Technology, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:  (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile’s medical devices was materially smaller; (2) to induce sales growth and share gains, Tactile engaged in illegal sales and marketing activities; and (3) Tactile’s revenues were in part the product of unlawful conduct and thus unsustainable.

If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]

Yield10 Bioscience Announces Collaboration with Rothamsted Research to Develop Advanced Technology for Producing Omega-3 Nutritional Oils in Camelina

WOBURN, Mass. and HARPENDEN, U.K., Nov. 12, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has signed a collaboration agreement with UK-based Rothamsted Research to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina sativa. The technology developed by Rothamsted could enable the sustainable, plant-based production of omega-3 (DHA+EPA) nutritional oils that closely mimic the composition of southern hemisphere fish oil, an important ingredient in aquaculture feed. Omega-3 oils are also essential for human nutrition and have demonstrated benefits in heart health.

Rothamsted Research is a world-leading nonprofit research center based in Harpenden, UK that focuses on strategic agricultural science to the benefit of farmers and society worldwide. Over the last decade, the team led by Professor Johnathan Napier, Ph.D., Science Director, has demonstrated the production of DHA+EPA oils in Camelina seed. In addition, Prof. Napier’s team has carried out multi-year field trials and multiple feeding studies using the DHA+EPA Camelina oil in different fish species including salmon. Under the agreement, Yield10 will provide support to Prof. Napier’s ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. As part of the agreement, Yield10 has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the omega-3 technology.

“Yield10 shares our vision for developing Camelina as a commercial crop for omega-3 oils based on a land-based route to production,” said Professor Angela Karp, Rothamsted director and chief executive officer. “Successful commercialization of this technology could have significant benefits, offering sustainable production of an oil essential for nutrition and wellness to consumers, as well as providing crop diversification to growers. Yield10 has described numerous innovations for improving the performance of Camelina and has demonstrated commitment and leadership in the development of Camelina as a new commercial crop. We look forward to advancing our mission of improving sustainable agriculture working with the Yield10 team.”

“Yield10 is developing Camelina as a platform crop for the production of nutritional oils and PHA biomaterials and we believe there is significant market opportunity for omega-3 oils produced in Camelina and the technology developed by Professor Napier and his team at Rothamsted is highly complementary to our development efforts in Camelina,” said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. “The Rothamsted team has successfully illustrated the key steps in a potential path for commercial development for the technology including stably deploying the DHA+EPA omega-3 oil pathway in Camelina, conducting field tests at scale in the UK and Canada, and publishing feeding studies to demonstrate the nutritional properties of the oil. Under this collaboration, we will have the opportunity to further assess the omega-3 oil technology and ongoing progress by Rothamsted while Yield10 continues to focus on developing elite varieties of Camelina and establishing a strategic business plan to identify opportunities for commercial development for this high value oil.”

About
Prof. Napier and
R
esearch
Related to
P
roducing
Omega
-3 oils in Camelina

Prof.
Napier is an internationally recognized leading pioneer in plant biotechnology and an advocate for the power of GM plants to deliver benefits for the public good. He has made key discoveries in understanding the biosynthesis of omega-3 long chain polyunsaturated fatty acids (omega-3 fish oils) in transgenic plants.


Selected


Recent Publications


Napier, J.A., Haslam, R.P., Olsen, R.E., Tocher, D.R., and Betancor, M.B. 2020. Agriculture can help aquaculture become greener. Nature Food 1, 680-683 (2020).

Han, L., Usher, S. L., Sandgrind, S., Hassall, K. L., Sayanova, O. V., Michaelson, L. V., Haslam, R. P. and Napier, J. A. 2020. High level accumulation of EPA and DHA in field-grown transgenic Camelina – a multi-territory evaluation of TAG accumulation and heterogeneity. Plant Biotechnol J. 2020;10.1111/pbi.13385. doi:10.1111/pbi.13385

West, A. L., Miles, E.A., Lillycrop K. A., Han, L., Sayanova, O. V., Napier, J. A. and Calder, P. C. 2019. Postprandial incorporation of EPA and DHA from transgenic Camelina sativa oil into blood lipids is equivalent to that from fish oil in healthy humans. Br J Nutr. 2019;121(11):1235-1246. doi:10.1017/S0007114519000825

Betancor, M. B., Li, K., Sprague, M., Bardal, T., Sayanova, O. V., Usher, S., Han, L., Måsøval, K., Torrissen, O., Napier, J. A., Tocher, D. R. and Olsen, R. E. 2017. An oil containing EPA and DHA from transgenic Camelina sativa to replace marine fish oil in feeds for Atlantic salmon (Salmo salar L.): Effects on intestinal transcriptome, histology, tissue fatty acid profiles and plasma biochemistry. PLoS One. 2017;12(4):e0175415. Published 2017 Apr 12. doi:10.1371/journal.pone.0175415

Usher, S., Han, L., Haslam, R.P. ., Michaelson, L. V., Sturtevant, D., Aziz, M., Chapman, K. D., Sayanova, O. V. and Napier, J. A. 2017. Tailoring seed oil composition in the real world: optimising omega-3 long chain polyunsaturated fatty acid accumulation in transgenic Camelina sativaScientific Reports 7 (1), 6570 (2017).

About Rothamsted
Research

Rothamsted Research is the longest-running agricultural research institute in the world. We work from gene to field with a proud history of ground-breaking discoveries, from crop treatment to crop protection, from statistical interpretation to soils management. In 1843, our founders were the pioneers of modern agriculture, and we are known for our imaginative science and our collaborative influence on fresh thinking and farming practices. Through independent science and innovation, Rothamsted has made significant contributions to improving agri-food systems in the UK and internationally. In terms of the institute’s economic contribution, the cumulative impact of our work in the UK was calculated to exceed £3000 million a year in 20151. Rothamsted Research is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from other national and international funding streams, and from industry. It is also supported by the Lawes Agricultural Trust (LAT).

For more information, visit the Rothamsted website or follow on Twitter @Rothamsted

1Rothamsted Research and the Value of Excellence: A synthesis of the available evidence, by Séan Rickard (Oct 2015)

About
Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations for sustainable global food security. The Company uses its “Trait Factory” including the “GRAIN” big data mining trait gene discovery tool as well as the Camelina oilseed “Fast Field Testing” system to develop high value seed traits for the agriculture and food industries. As a path toward commercialization of novel traits, Yield10 is pursuing a partnering approach with major agricultural companies to drive new traits into development for canola, soybean, corn, and other commercial crops. The Company is also developing improved Camelina varieties as a platform crop for the production and commercialization of nutritional oils, proteins, and PHA biomaterials. The Company’s expertise in oilseed crops also extends into canola, where it is currently field-testing novel yield traits to generate data to drive additional licensing opportunities. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the company, please visit www.yield10bio.com, or follow the Company on Twitter, Facebook and LinkedIn.

(YTEN-G)

Safe Harbor for
Forward-Looking
Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, whether the technology developed by Rothamsted could enable the sustainable, plant-based production of omega-3 nutritional oils that closely mimic the composition of southern hemisphere fish oil, the fact that Yield10 researchers will collaborate with Prof. Napier and his team on advancing the development of Camelina modified to produce omega-3 nutritional oils, whether successful commercialization of this technology could have benefits, offering sustainable production of an oil essential for nutrition and wellness to consumers, as well as providing crop diversification to growers, and whether there is significant market opportunity for omega-3 oils produced in Camelina, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience’s filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

Contacts:

Rothamsted Research:

James Clarke, Head of Communications
+44 7964 832719, [email protected]

Yield10
Bioscience
:

Lynne H. Brum, (617) 682-4693, [email protected]

Investor Relations:
Bret Shapiro, (561) 479-8566, [email protected]
Managing Director, CORE IR

Media Inquiries:
Eric Fischgrund, [email protected]
FischTank PR

Franklin Limited Duration Income Trust Announces Sources of Monthly Dividend Distribution

Franklin Limited Duration Income Trust Announces Sources of Monthly Dividend Distribution

SAN MATEO, Calif.–(BUSINESS WIRE)–
The Franklin Limited Duration Income Trust [NYSE:FTF] (CUSIP 35472T101) has declared a dividend of $0.0775 per common share payable November 13, 2020, to shareholders of record as of October 30, 2020. It is currently estimated that $0.0531 per share represents net investment income and $0.0244 per share represents return of principal.

The Fund adopted a managed distribution plan and will make monthly distributions to common shareholders at an annual minimum fixed rate of 10 percent, based on the average monthly net asset value (NAV) of the Fund’s common shares. The Fund will calculate the average NAV from the previous month based on the number of business days in that month on which the NAV is calculated. The distribution will be calculated as 10 percent of the previous month’s average NAV, divided by 12. Management will generally distribute amounts necessary to satisfy the Fund’s plan and the requirements prescribed by excise tax rules and Subchapter M of the Internal Revenue Code. The plan is intended to provide shareholders with a constant, but not guaranteed, fixed minimum rate of distribution each month and is intended to narrow the discount between the market price and the NAV of the Fund’s common shares, but there is no assurance that the plan will be successful in doing so.

Under the managed distribution plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution level. No conclusions should be drawn about the Fund’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s managed distribution plan.

The Board may amend the terms of the plan or terminate the plan at any time without prior notice to the Fund’s shareholders. The amendment or termination of the plan could have an adverse effect on the market price of the Fund’s common shares. The plan will be subject to the periodic review by the Board, including a yearly review of the annual minimum fixed rate to determine if an adjustment should be made.

In compliance with Rule 19a-1 of the Investment Company Act of 1940, shareholders will receive a notice that details the source of income for each dividend, such as net investment income, gain from the sale of securities and return of principal. Please note: Determination of the actual source of the Fund’s dividend can only be made at year-end. The actual source amounts of all Fund dividends will be included in the Fund’s annual or semiannual reports.

In addition, the tax treatment may differ from the accounting treatment used to calculate the source of the Fund’s dividends as shown on your statement. Please refer to your Form 1099-DIV for the character and amount of distributions for income tax reporting purposes. Since each shareholder’s tax situation is unique, please consult your tax advisor as to the appropriate treatment of Fund distributions.

You may request a copy of the Fund’s current Report to Shareholders by contacting Franklin Templeton’s Fund Information Department at 1-800/DIAL BEN® (1-800-342-5236) or by visiting franklintempleton.com. All investments involve risks, including possible loss of principal. Interest rate movements and mortgage prepayments will affect the Fund’s share price and yield. Bond prices generally move in the opposite direction of interest rates. As the prices of bonds in a fund adjust to a rise in interest rates, the fund’s share price may decline. Investments in lower-rated bonds include higher risk of default and loss of principal. The Fund is actively managed but there is no guarantee that the manager’s investment decisions will produce the desired results. For portfolio management discussions, including information regarding the Fund’s investment strategies, please view the most recent Annual or Semi-Annual Report to Shareholders which can be found at franklintempleton.com or sec.gov.

Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 165 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company brings extensive capabilities in equity, fixed income, multi-asset solutions and alternatives. With offices in more than 30 countries and approximately 1,300 investment professionals, the California-based company has over 70 years of investment experience and approximately $1.4 trillion in assets under management as of October 31, 2020. For more information, please visit franklintempleton.com.

Copyright © 2020. Franklin Templeton. All rights reserved.

Franklin Templeton

Shareholders/Financial Advisors: (800) 342-5236

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA: